In the latest session, Resmed Inc. (NYSE: RMD) closed at $173.72 down -0.14% from its previous closing price of $173.96. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 1612996 shares were traded.
Ratios:
For a deeper understanding of Resmed Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 121.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 26.55. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.30.
On October 27, 2023, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also lowered its target price recommendation from $180 to $169.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on October 12, 2023, whereas the target price for the stock was revised from $273 to $202.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 22 when FARRELL PETER C sold 10,935 shares for $182.66 per share. The transaction valued at 1,997,434 led to the insider holds 157,404 shares of the business.
Sandercock Brett sold 3,000 shares of RMD for $457,860 on Nov 27. The Chief Financial Officer now owns 92,962 shares after completing the transaction at $152.62 per share. On Nov 15, another insider, Farrell Michael J., who serves as the Chief Executive Officer of the company, sold 5,678 shares for $152.04 each. As a result, the insider received 863,281 and left with 440,986 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 25.59B and an Enterprise Value of 26.77B. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.78, and their Forward P/E ratio for the next fiscal year is 21.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.67 while its Price-to-Book (P/B) ratio in mrq is 5.70. Its current Enterprise Value per Revenue stands at 5.94 whereas that against EBITDA is 18.72.
Stock Price History:
Over the past 52 weeks, RMD has reached a high of $243.52, while it has fallen to a 52-week low of $132.24. The 50-Day Moving Average of the stock is 178.56, while the 200-Day Moving Average is calculated to be 178.59.
Shares Statistics:
For the past three months, RMD has traded an average of 915.80K shares per day and 744.3k over the past ten days. A total of 147.06M shares are outstanding, with a floating share count of 145.90M. Insiders hold about 0.81% of the company’s shares, while institutions hold 56.33% stake in the company. Shares short for RMD as of Feb 15, 2024 were 6.58M with a Short Ratio of 7.19, compared to 5.89M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.48% and a Short% of Float of 5.11%.
Dividends & Splits
According to the company, the forward annual dividend rate for RMD is 1.88, from 1.84 in the trailing year. Against a Trailing Annual Dividend Yield of 1.06%, it implies a Forward Annual Dividend Yield of 1.11%. The stock’s 5-year Average Dividend Yield is 0.88. The current Payout Ratio is 28.91% for RMD, which recently paid a dividend on Mar 14, 2024 with an ex-dividend date of Feb 07, 2024. Stock splits for the company last occurred on Aug 31, 2010 when the company split stock in a 2:1 ratio.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of $1.9 for the current quarter, with a high estimate of $1.98 and a low estimate of $1.81, while EPS last year was $1.68. The consensus estimate for the next quarter is $1.96, with high estimates of $2.09 and low estimates of $1.86.
Analysts are recommending an EPS of between $8.26 and $7.24 for the fiscal current year, implying an average EPS of $7.45. EPS for the following year is $8.13, with 12 analysts recommending between $8.92 and $7.33.
Revenue Estimates
A total of 17 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $4.7B, while the lowest revenue estimate was $4.59B, resulting in an average revenue estimate of $4.63B. In the same quarter a year ago, actual revenue was $4.22B, up 9.70% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $4.93B in the next fiscal year. The high estimate is $5.05B and the low estimate is $4.42B. The average revenue growth estimate for next year is up 6.30% from the average revenue estimate for this year.
